Introduction {#section1-0269881108100255}
============

Substance P-preferring, neurokinin receptors (NK1R) are concentrated in brain regions that govern mood, cognition and motor performance, including the response to reward and stress ([@bibr50-0269881108100255]). Mice with functional ablation of the NK1R gene ([@bibr15-0269881108100255]) (NK1R−/−) are hyperactive when compared with their wild-type (NK1R+/+) ([@bibr31-0269881108100255]; [@bibr21-0269881108100255]) and their response to reward is disrupted. For instance, NK1R−/− mice develop conditioned place preference with cocaine, but not *d*-amphetamine or morphine ([@bibr40-0269881108100255]; [@bibr23-0269881108100255]). Further, they are more sensitive to the depressant effects of alcohol than their wild-type ([@bibr24-0269881108100255]), and they do not self-administer morphine ([@bibr51-0269881108100255]) or develop locomotor sensitization when given this opiate ([@bibr51-0269881108100255]; [@bibr23-0269881108100255]).

There is evidence that α~2A~-autoreceptors are desensitized in the locus coeruleus of NK1R−/− mice ([@bibr31-0269881108100255]; [@bibr21-0269881108100255]). This is consistent with reports that antagonism of NK1R increases burst-firing of noradrenergic neurones in this nucleus and release of noradrenaline from their terminals ([@bibr31-0269881108100255]; [@bibr21-0269881108100255]; [@bibr27-0269881108100255]). Excessive noradrenergic transmission would disrupt attentional aspects of task performance ([@bibr6-0269881108100255]; [@bibr10-0269881108100255]) and augment release of serotonin in the forebrain ([@bibr22-0269881108100255]; [@bibr27-0269881108100255]); both these actions would impair response control ('impulsivity') ([@bibr67-0269881108100255]).

Hyperactivity, inattention, and impulsivity are core features of attention deficit hyperactivity disorder (ADHD), which affects between 2% and 5% of children in the UK and continues into adulthood. The disruption of the regulation of noradrenergic (reviewed by [@bibr11-0269881108100255]) and serotonergic (reviewed by [@bibr41-0269881108100255]) transmission is thought to be amongst the neurobiological abnormalities underlying ADHD. To date, our findings suggest that all these behavioural and neurochemical changes can be secondary to blunted NK1R function. It follows that the disruption of NK1R could be a causal factor in ADHD.

Mounting evidence suggests that disruption of dopaminergic transmission in corticostriatal circuits of the brain is another prominent feature of ADHD (reviewed by [@bibr48-0269881108100255]). The hyperactivity of NK1R−/− mice, together with their atypical response to certain rewarding stimuli, is consistent with this proposal. On this basis, the present experiments investigated whether dopaminergic transmission is abnormal in NK1R−/− mice. First, their locomotor response to the psychostimulants, methylphenidate (which blocks reuptake of dopamine) or *d*-amphetamine (a dopamine releasing agent), was compared with that of wild-type mice. Then, we used microdialysis to monitor extracellular dopamine in the dorsal striatum and prefrontal cortex (PFC): we compared both basal efflux and the effects of an acute challenge with an NK1R antagonist and/or *d*-amphetamine in the two genotypes. In both behavioural and neurochemical experiments, we tested whether the NK1R−/− mouse phenotype was mimicked by treating wild-types with an NK1R antagonist. The findings from all these experiments (described below) consolidated the status of NK1R−/− mice as a model of ADHD.

Prompted by the above evidence, we went on to genotype polymorphisms near or within the human TACR1 gene (the human equivalent of NK1R) in an ADHD case--control sample. However, ADHD is not a unitary disorder. In one subgroup, children also have conduct disorders and a greatly increased risk of criminality and alcoholism in adulthood. A second subgroup has been linked to parents with affective disorders: one study of parents with bipolar disorder (BPAD) found that a high proportion of their children were diagnosed as having ADHD ([@bibr32-0269881108100255]). Comorbidity between BPAD and alcoholism is also well established. Against this background, it is striking that the TACR1 gene, which is found on chromosome 2, is localised within a region linked to a combined alcoholism and conduct disorder phenotype ([@bibr18-0269881108100255]; [@bibr66-0269881108100255]). The findings reported here strongly suggest that polymorphisms of TACR1 could distinguish a genetically defined subgroup of ADHD patients who have increased vulnerability to comorbid bipolar disorder and alcoholism.

We believe this is the first example of a mutant mouse phenotype leading to the discovery of a genetic susceptibility to a psychiatric disorder.

Materials and methods {#section2-0269881108100255}
=====================

Subjects {#section3-0269881108100255}
--------

### Mice {#section4-0269881108100255}

All procedures complied with the UK Animals (Scientific Procedures) Act, 1986. We used male mice (25--35 g) with a 129/Sv × C57BL/6 genetic background backcrossed with an outbred MF1 strain. The colony was maintained at UCL as described previously ([@bibr31-0269881108100255]). The genotype of each mouse was verified *postmortem*.

### Humans {#section5-0269881108100255}

UK National Health Service (NHS) Multicenter Research Ethics Committee (MREC) and Local Research Ethics Committee (LREC) approval was obtained. All subjects, or their guardians or parents, signed an approved consent form after reading an information sheet. DNA samples were collected from 450 ADHD probands from NHS services in the UK.

### ADHD patients {#section6-0269881108100255}

All were of white European origin. ADHD subjects were selected only if both parents were English, Scottish or Welsh. Subjects were referred for research assessment if experienced clinicians diagnosed ADHD (*DSM-IV* criteria) and an IQ of \>70. Only individuals fulfilling the recruitment criteria after the completion of research assessments were included in the study. In the ADHD subsample, assembled at Cardiff University, parental information on the child\'s symptoms was obtained using the Child and Adolescent Psychiatric Assessment (CAPA) ([@bibr4-0269881108100255]). Data on the pervasiveness of symptoms were obtained from teachers, using the Child ADHD Teacher Telephone Interview (ChATTI) ([@bibr33-0269881108100255]). For the second subsample, information on ADHD symptoms at school was obtained with the Conners Teacher questionnaire (long form) and scored as present if rated greater than one. HYPESCHEME, a computerized operational criteria checklist and diagnostic algorithm for *DSM-IV* and *International Classification of Diseases (10th Revision)*, was used to confirm the diagnosis of the London-based subsample. HYPESCHEME data sheets were completed with data from the parent and school questionnaires together with the review of case notes. The HYPESCHEME diagnoses were checked against researcher-applied *DSM-IV* criteria and discrepancies were reviewed by two researchers. Situational pervasiveness was operationalized as the presence of one or more ADHD symptoms at home and at school, together with parental descriptions of impairment from ADHD symptoms, in more than one setting. If necessary, final consensus was agreed with a senior clinical researcher at a case conference.

### Controls {#section7-0269881108100255}

Screening of the controls for ancestry was carried out using a questionnaire to ensure that both parents were English, Scottish or Welsh with at least three grandparents having the same origins. One grandparent was allowed to be of another Caucasian European origin but not of Jewish or non-European Union (EU) ancestry (based on pre-2004 EU membership). All subjects were interviewed by a psychiatrist and recruited if there was no first-degree family history of any psychiatric disorder, according to self-report, including dissocial personality disorder, ADHD, schizophrenia, alcoholism, bipolar or unipolar disorder. Subjects were then interviewed with the SADS-L schedule and included only if there was no current or lifetime history of any research diagnostic criteria (RDC)-defined mental disorder ([@bibr59-0269881108100255]; [@bibr60-0269881108100255]).

Mouse behaviour {#section8-0269881108100255}
---------------

Drug-naïve mice were placed individually in a light/dark exploration box (LDEB). They were allowed 90-min habituation in the dark zone (170 lux) as in the microdialysis studies, (below) (see [@bibr31-0269881108100255]; [@bibr21-0269881108100255]). After 60 min, the mice were randomly assigned to groups given saline (10 mL/kg) or *d*-amphetamine (2.5 mg/kg, i.p.). After a further 30 min, they were transferred to a novel, light zone (350 lux) of the LDEB and allowed to commute between the compartments. Behaviour was recorded for 30 min and their locomotor activity (number of lines crossed) was scored blind. In a second experiment, methylphenidate (2.5 mg/kg; i.p.) replaced *d*-amphetamine but the protocol was otherwise the same.

When experiments involved two successive treatments, each mouse was placed in the LDEB, as before. After a further 30 min, they were randomly assigned to groups given vehicle (Tween 80 in 0.9% saline) or an NK1R antagonist: RP 67580 (5 or 10 mg/kg, i.p.). These test doses of RP 67580 are within the range of those reported to modify the behaviour of mice ([@bibr54-0269881108100255]; [@bibr68-0269881108100255]; [@bibr30-0269881108100255]). After 30 min, pairs of subgroups were given either saline or *d*-amphetamine (2.5 mg/kg i.p.), and after a total of 90-min habituation, their locomotor activity was monitored. This experiment was repeated with another NK1R antagonist, L 733060, using the same doses (5 or 10 mg/kg, i.p.) so as to enable comparison of the effects of the two antagonists. Both compounds are believed to penetrate the blood-brain barrier ([@bibr9-0269881108100255]; [@bibr19-0269881108100255]).

Microdialysis {#section9-0269881108100255}
-------------

A microdialysis probe (Cuprophan membrane, dialysis window of 1.0 mm) was implanted in halothane-anaesthetised mice in either the prefrontal cortex ((mm relative to Bregma): AP +2.1, ML+1.0, DV −2.0) or the dorsal striatum ((mm) AP + 1.10, ML+1.5, DV −3.3) ([@bibr44-0269881108100255]) ([Figure 1](#fig1-0269881108100255){ref-type="fig"}). After overnight recovery, the probes were perfused with Ringer\'s solution (1.5 μL/min): stable (basal) efflux was confirmed in the home cage, before the mice were transferred to the LDEB where they were given either vehicle or an NK1R antagonist followed by saline or *d*-amphetamine at 30 and 60 min, respectively (see above). After 90 min, the mice were confined within the light zone of the LDEB (where they are most active).

![Schematic illustration (left) and photomicrograph (right) showing the typical location of the microdialysis probe track in the prefrontal cortex and dorsal striatum. Distances anterior to Bregma are indicated in mm (as defined in NK1(TACR1) gene mutation increases vulnerability to ADHD 29. [@bibr44-0269881108100255]. The Mouse Brain in Stereotaxic Coordinates. Second edition. London: Academic Press. Reproduced with permission from Elsevier)](10.1177_0269881108100255-fig1){#fig1-0269881108100255}

Microdialysis samples were collected at 20-min intervals throughout the experiment and their dopamine content was analysed by high performance liquid chromatography coupled to an electrochemical detector (HPLC-ECD). The mobile phase comprised (mM) NaH2PO4 83, octanesulfonic acid 0.23, ethylenediaminetetraacetic acid disodium salt (EDTA) 0.84, and methanol 17% (adjusted to pH 4.0 with orthophosphoric acid) and was pumped through the HPLC system at 1 mL/min by a Shimadzu LC 6A isocratic dual-piston pump. Microdialysis samples were loaded into a rheodyne injection port fitted with a 50-μL loop and the solutes were separated on a 5-μM (4.6 × 250 mm) octadecylsilane column protected by a 7-μM aquapore guard column (4.6 × 30 mm). Dopamine content was measured with a Coulochem II detector with the conditioning electrode set at −280 mV and the measuring electrode set at +140 mV. A guard cell, set at +350 mV, was used to condition the mobile phase. The maximum sensitivity of the system was 5∼8 fmol (twice the baseline amplitude).

Human DNA extraction and SNP characterization {#section10-0269881108100255}
---------------------------------------------

Genomic DNA from all sources was extracted from whole blood samples using standard cell lysis, proteinase K digestion, and phenol/chloroform ethanol precipitation method ([@bibr53-0269881108100255]). Single nucleotide polymorphism (SNP) markers were genotyped using KASPar, which employs a universal fluorescent primer method of end-labelling amplified PCR product (KBioscience, Hoddesdon, UK), which was a modified Amplifluor SNP genotyping method. Seventeen percent of the samples from each microtitre plate were reduplicated to expose possible errors and to confirm the reproducibility of genotypes.

Statistics {#section11-0269881108100255}
----------

### Mouse {#section12-0269881108100255}

Behavioural data were analysed using the general linear model (SPSS (PC+)) with 'genotype' and 'drug1' and 'drug2' (when appropriate) as main factors in two-way or three-way ANOVA, followed by *post hoc* tests (LSD: see [@bibr31-0269881108100255]). Microdialysis data were analysed using repeated measures ANOVA (SPSS PC^+^) with 'time' as a within-subjects factor. Comparisons of blocks of data in different treatment groups were carried out on time-matched samples. When clusters of consecutive samples ('bin') within individual treatment groups were compared, bin was treated as a within-subjects factor. Raw data were analysed routinely but, for the dorsal striatum, the incremental (net) change in efflux was also analysed; this was calculated by the subtraction of mean efflux in the basal samples of each mouse from all samples in the series. A significant effect on main factor(s), or relevant interactions between them, was the criterion for progressing to *post hoc* comparisons of group means. The Greenhouse-Geisser 'ε' correction was applied to compensate for violation of sphericity of the variance-covariance matrix. Statistical significance was set at *P* ≤ 0.05.

### Human {#section13-0269881108100255}

Human genetic data were first analysed to confirm Hardy-Weinberg equilibrium (HWE). Markers lacking HWE were repeated using an alternative Taqman method. Before any association analysis, the genotype data were assessed using the SCANGROUP program in GENECOUNTING ([@bibr69-0269881108100255]). This program highlights potential genotyping errors by identifying significant differences in haplotypic frequencies between any single 96 well microtitre-plate when compared to haplotypic frequencies in all other plates combined.

Allelic association analysis with ADHD was carried out using a two-tailed chi-squared test for biallelic SNPs. The multilocus genotypes were then analysed for haplotypic association with ADHD using HAPLOVIEW, which estimates the maximum likelihood of haplotype frequencies from phase unknown case-control data. Monte Carlo significance of any haplotypic associations with ADHD was then obtained with a permutation test ([@bibr57-0269881108100255]). HAPLOVIEW was also used to calculate pair-wise tests of linkage disequilibrium with d′ and r^2^ for all markers visualised using Locus View 2.022.

Results {#section14-0269881108100255}
=======

Psychostimulants prevent hyperactivity of NK1R−/− mice {#section15-0269881108100255}
------------------------------------------------------

The locomotor activity of NK1R−/− mice was more than 2-fold greater than that of their wild-type counterparts. An acute *d*-amphetamine challenge increased the activity of NK1R+/+ mice but reduced that of NK1R−/− mice (without inducing stereotypy \[*P* \< 0.05\]: genotype × drug: *F*(1,36) = 14.9, *P* \<0.001) ([Figure 2A](#fig2-0269881108100255){ref-type="fig"}). The motor response to the dopamine reuptake inhibitor, methylphenidate, similarly depended on genotype \[genotype × drug: *F*(1,43) = 11.1, *P* \<0.01\] ([Figure 2A](#fig2-0269881108100255){ref-type="fig"}); the locomotor activity of NK1R+/+ mice was increased by this drug, but that of NK1R−/− mice did not differ from drug-free wild-types. Thus, the behaviour of NK1R−/− mice given either of these drugs did not differ from the NK1R+/+ phenotype ([Figure 2A](#fig2-0269881108100255){ref-type="fig"}).

![Effects of psychostimulants and NK1R antagonists on the locomotor activity of NK1R+/+ and NK1R−/− mice. (A) Animals were given saline ('Veh': 10 mL/kg, i.p.), *d*-amphetamine ('*d*-AMP': 2.5 mg/kg, i.p.; *N* = 10) or methylphenidate ('MPH': 2.5 mg/kg, i.p.; *N* = 12--13). Bars show mean ± s.e. mean. The data were analysed by ANOVA with *post hoc* comparison of pairs of data (LSD test). Lines linking treatment groups indicate a statistically significant difference between the means at *P* ≤ 0.05 (or less). (B) Locomotor activity of NK1R+/+ mice and NK1R−/− mice following the administration of saline (Sal) or *d*-amphetamine (*d*-AMP: 2.5 mg/kg i.p.). These two treatments were assigned to mice that had been pretreated with either vehicle (Veh: Tween 80 in 0.9% saline) or an NK1R antagonist (RP 67580 ('RP') or L 733060 ('L')) at the doses indicated in parentheses (5 or 10 mg/kg i.p.). Bars show mean ± s.e. mean locomotor activity in the light zone of the LDEB per unit time. All the data from this experiment, which was fully randomised for each NK1R antagonist, were first analysed by multifactorial (three-way) ANOVA. When there was a difference in the main factors, or a relevant interaction between them, pairs of data were compared using a *post hoc* one-way ANOVA and LSD test. Lines linking pairs of treatment groups indicate differences between the means at *P* ≤ 0.05 (or less)](10.1177_0269881108100255-fig2){#fig2-0269881108100255}

Behaviour of NK1R−/− mice resembles that of wild-type (NK1R+/+) mice given an NK1R antagonist {#section16-0269881108100255}
---------------------------------------------------------------------------------------------

Next, we compared the effects of NK1R antagonists (RP 67580 or L 733060; 5 and 10 mg/kg, i.p.) on spontaneous and *d*-amphetamine-evoked locomotor activity in the two genotypes. There was an NK1R antagonist × *d*-amphetamine × genotype interaction with RP 67580 \[*F*(2,33) = 6.5, *P* \< 0.01\] and L 733060 \[*F*(2,24) = 3.3, *P* = 0.05\] ([Figure 2B](#fig2-0269881108100255){ref-type="fig"}). Both these compounds increased the locomotor activity of NK1R+/+ mice \[*P* \< 0.05, in both cases\] but neither affected NK1R−/− mice. *d*-Amphetamine reduced the motor activity of NK1R−/− mice and that of NK1R+/+ mice pretreated with an NK1R antagonist \[*P* \< 0.05 in both cases\].

Lack of functional NK1R disrupts regulation of dopamine efflux in the dorsal striatum and prefrontal cortex {#section17-0269881108100255}
-----------------------------------------------------------------------------------------------------------

Basal efflux of dopamine in the dorsal striatum did not differ in the two genotypes \[NK1R+/+: 24.5 ± 0.7 fmol/20 min; NK1R−/−: 25.6 ± 3.2 fmol/20 min; *N* =16--17\] and was unaffected by systemic administration of RP 67580 ([Figure 3A](#fig3-0269881108100255){ref-type="fig"}). However, the dopamine response to *d*-amphetamine differed in NK1R−/− and NK1R+/+ mice \[genotype × amphetamine: *F*(1,13) = 4.5, *P* = 0.05\]. Specifically, *d*-amphetamine caused an incremental increase in dopamine efflux in NK1R+/+ mice \[T~80~-T~120~ *versus* basal samples: *F*(1,3) = 14.7, *P* = 0.03\] but not in NK1R−/− mice ([Figure 3B](#fig3-0269881108100255){ref-type="fig"}). Furthermore, pretreatment with the NK1R antagonist prevented the dopamine response to *d*-amphetamine in the wild-types \[[Figure 3B](#fig3-0269881108100255){ref-type="fig"}: genotype × RP 67580: *F*(1,13) = 5.7, *P* \< 0.05\].

![Effect of *d*-amphetamine on dopamine efflux in the dorsal striatum of NK1R+/+ and NK1R−/− mice. Stable basal efflux was first established in the home cage before the transfer of the mice to the dark zone of the LDEB for 90 min where they were given a first injection (at 30 min) of either vehicle (Veh: Tween 80 in 0.9% saline) or RP 67580 ('RP', 5 mg/kg. i.p.) followed by a second injection (at 60 min) of either (A) saline (sal) or (B) *d*-amphetamine ('*d*-AMP': 2.5 mg/kg i.p.), as indicated by the arrows. The mice were then transferred to the light zone of the LDEB. Points show mean ± s.e. mean efflux of the incremental increase ('net') from baseline: Net efflux was calculated, as described in Methods. The experiment was fully randomised across the eight groups but the data are illustrated in two graphs for clarity. Results were first analysed by multifactorial (three-way) ANOVA. When there was a difference in the main factors, or a relevant interaction between them, time-matched bins of data were compared using (*post hoc*) two-way repeated measures ANOVA (*N* = 3 or 4 per cell). Bins of data that differ by *P* ≤ 0.05 (or less) are indicated by the solid bar. (A) There was no difference in basal efflux in saline injected mice after treatment with RP 67580. (B) Comparison of efflux in the sample bin, T~80~-T~120~ (*i.e*. after treatment with *d*-amphetamine) with that of the three basal samples revealed an interaction between bin × genotype × RP/vehicle (\$: *F*~1,13~ = 11.7; *P* \< 0.01). Further, within the sample bin, T~80~-T~120~, there was a genotype × RP/vehicle interaction (\#: *F*~1,13~ = 5.7; *P* \< 0.05)](10.1177_0269881108100255-fig3){#fig3-0269881108100255}

In the PFC, dopamine efflux in NK1R−/− mice was less than half that of their wild-type \[[Figure 4A](#fig4-0269881108100255){ref-type="fig"} and [4B](#fig4-0269881108100255){ref-type="fig"}: *F*(1,18) = 182.2, *P* \< 0.001\]. Moreover, efflux in NK1R+/+ mice given RP 67580 progressively declined to that of NK1R−/− mice ([Figure 4A](#fig4-0269881108100255){ref-type="fig"}). *d*-Amphetamine did not affect dopamine efflux in vehicle-pretreated mice of either genotype ([Figure 4B](#fig4-0269881108100255){ref-type="fig"}) or that in NK1R+/+ mice given RP 67580 ([Figure 4A](#fig4-0269881108100255){ref-type="fig"} and [4B](#fig4-0269881108100255){ref-type="fig"}).

![Effect of *d*-amphetamine on dopamine efflux in the PFC of NK1R+/+ and NK1R−/− mice. Mice were given vehicle (Veh: Tween 80 in 0.9% saline) or RP 67580 ('RP', 5 mg/kg. i.p.) followed by a second injection of (A) saline (Sal) or (B) *d*-amphetamine (*d*-AMP: 2.5 mg/kg i.p.), as indicated by the arrows (see legend to [Figure 3](#fig3-0269881108100255){ref-type="fig"} for further details). Points show mean ± s.e. mean dopamine efflux in the LDEB (*N* = 3 or 4 per cell). Across the eight groups, there was a main effect of genotype in the basal samples (\*: *F*~1,18~ = 181.2; *P* \< 0.001). When comparing efflux in the final bin of three samples with that in the basal samples, there was a bin × genotype × RP/vehicle interaction (\$: *F*~1,18~ = 6.7; *P* = 0.02). There was also an interaction (\#) between genotype × RP/ vehicle in the final bin (*F*~1,18~ = 5.9; *P* = 0.03)](10.1177_0269881108100255-fig4){#fig4-0269881108100255}

SNPs in TACR1 (human NK1R) gene are associated with ADHD {#section18-0269881108100255}
--------------------------------------------------------

In an earlier unpublished study, which used seven SNP 'tagging' markers that capture most of the haplotypic variation in the region of the TACR1 gene, we identified a single SNP (rs3771856) that was associated with alcoholism. More recently, in part of a genome-wide association study ([@bibr58-0269881108100255]), we observed an association between a further 18 SNPs at, or within, 20 kb of TACR1 and bipolar disorder, including polymorphisms of TACR1. In view of the well established comorbidity of ADHD with conduct disorder and alcoholism, we decided to explore allelic and haplotypic association between genetic markers at, or within, 20 kb of the TACR1 gene with ADHD. We focussed on eight SNPs that had already been shown to be significantly associated with bipolar disorder or alcoholism or had shown a strong trend towards significance (see [Table 1](#table1-0269881108100255){ref-type="table"}).

###### 

Tests of allelic association between genetic markers at TACR1 with ADHD in the samples from the University of Cardiff and Institute of Psychiatry, London

  \#   SNP Code     Associated Allele   Case allele counts   Control allele counts   Case allele frequencies   Control allele frequencies   HW Cases   HW Controls   Allelic χ^2^   2 sided *P* value             
  ---- ------------ ------------------- -------------------- ----------------------- ------------------------- ---------------------------- ---------- ------------- -------------- ------------------- --------- ---------
  1    rs3886110    A                   367                  457                     437                       583                          0.445      0.428         0.884          0.637                 0.533   0.4654
  2    rs13012537   G                   355                  459                     431                       589                          0.436      0.423         0.905          0.461                 0.34    0.5596
  3    rs3771829    C                     89                 735                       64                      942                          0.108      0.064         0.356          0.979               11.651    0.0006
  4    rs3771833    A                   105                  693                       76                      928                          0.132      0.076         0.203          0.176               15.366    0.00008
  5    rs10203484   A                   296                  514                     351                       669                          0.365      0.344         0.382          0.389                 0.897   0.3435
  6    rs12477554   A                   339                  461                     431                       589                          0.424      0.423         0.709          0.848                 0.003   0.9589
  7    rs3771856    G                   431                  321                     604                       572                          0.573      0.514         0.273          0.462                 6.538   0.0106
  8    rs17011370   G                   781                    33                    946                         70                         0.959      0.931         0.673          0.776                 6.842   0.0089

SNPs numbered 3, 4, 7, 8 show allelic association with ADHD. All markers remained significant after correcting for the use of eight SNPs.

Four of these SNPs showed allelic or haplotypic association with ADHD (rs3771829: *P* = 0.0006; rs3771833: *P* = 0.00008; rs3771856: *P* = 0.0106; and rs1701137: *P* = 0.0089). Robust evidence for allelic association with ADHD remained after the correction for multiple testing ([Table 1](#table1-0269881108100255){ref-type="table"} and [Figure 5](#fig5-0269881108100255){ref-type="fig"}). We then tested for haplotypic association and found a single haplotype that was associated with ADHD. This consisted of the alleles C and A of the SNPs rs3771829 and rs3771833, respectively, which are tagging SNPs for haplotype block 2 of the TACR1 gene ([Table 2](#table2-0269881108100255){ref-type="table"}). The statistical significance of the association with ADHD remained after empirical tests of significance were applied, empirical *P* = 0.0028. Output from the Human Genome Browser (<http://genome.ucsc.edu/>) (March 2006 release) in [Figure 5](#fig5-0269881108100255){ref-type="fig"} shows the distances between markers, vis à vis, TACR1 together with the linkage disequilibrium relationships between adjacent markers in the ADHD case-control sample. As shown in [Figure 5](#fig5-0269881108100255){ref-type="fig"}, the associated SNPs are within the first intron of TACR1 or in the 5′ promoter region.

![Schematic diagram of NK1R/TACR1 gene structure and associated SNPs on human chromosome 2p12. Exons and introns of the TACR1 gene are shown according to the March 2006 release of the Human Genome Browser (<http://genome.ucsc.edu>). The gene is transcribed from the right of the diagram (5′) to the left (3′). The names and positions of the four SNP markers, found to show association with ADHD, are shown relative to the structure of the genes in the region. Three of the four SNPs were within the first intron of TACR1](10.1177_0269881108100255-fig5){#fig5-0269881108100255}

###### 

Haplotype analysis of SNP data from ADHD cases and controls at the TACR1 locus

  Block and SNPs   Haplotype   Freq.   Counts   Frequencies   χ^2^    Asymptotic *P* Value   χ^2^     Permutation *P* Value                                              
  ---------------- ----------- ------- -------- ------------- ------- ---------------------- -------- ----------------------- ------- --------- -------------- --------- ------------
  Block 1                                                                                                                                                                
      rs3886110    C           A       0.556    453.7         378.3   575.9                  444.1    0.545                   0.565     0.69    0.4062           0.69    0.9899
      &            A           G       0.421    356.5         475.5   423.9                  596.1    0.429                   0.416     0.316   0.574            0.316   0.9989
      rs13012537   A           A       0.015      15.5        816.5     13.1                 1007     0.019                   0.013     0.985   0.321            0.985   0.9517
  Block 2                                                                                                                                                                
      rs3771829    G           G       0.893    716.3         113.7   935.7                    84.3   0.863                   0.917   14.147    **2.00E-04**   14.147    **0.0008**
      &            C           A       0.083      89.2        740.8     63.6                 956.4    0.107                   0.062   12.281    **5.00E-04**   12.281    **0.0028**
      rs3771833    G           A       0.023      22.3        807.7     19.5                 1001     0.027                   0.019     1.267   0.2604           1.267   0.9166
  Block 3                                                                                                                                                                
      rs10203484   G           G       0.575    470.8         353.2   589                    431      0.571                   0.577     0.07    0.792            0.07    1
      &            A           A       0.354    301.8         522.2   351                    669      0.366                   0.344     0.98    0.3221           0.98    0.9526
      rs12477554   G           A       0.071      51.4        772.6   80                     940      0.062                   0.078     1.779   0.1823           1.779   0.813

SNP markers are combined into haplotypes using the program HAPLOVIEW. Two haplotypes show association with ADHD but only one was positively associated with ADHD and this remained significant after an empirical test of association (9,999 iterations). The associated haplotype comprised allele C from SNP rs3771829 and allele A from rs3771833.

Discussion {#section19-0269881108100255}
==========

The hyperactivity of NK1R−/− mice and its prevention by *d*-amphetamine or methylphenidate together, with disrupted monoamine transmission, all echo features of ADHD (see [@bibr17-0269881108100255]). Crucially, the prevention of hyperactivity by methylphenidate distinguishes these mutant mice from the spontaneously hypertensive rat ([@bibr2-0269881108100255]), which is the most widely studied model of this disorder. Both the hyperactivity and the atypical effects of *d*-amphetamine in NK1R−/− mice rest on the lack of functional NK1R rather than extraneous (e.g. developmental) changes. This is confirmed by our finding that NK1R antagonists (RP 67580 or L 733060) increased the locomotor activity of NK1R+/+ mice and that this was prevented by *d*-amphetamine. Neither of these antagonists affected the locomotor hyperactivity of the mutant mice and so their NK1R selectivity is assured.

We then used *in vivo* microdialysis to investigate whether the disruption of dopaminergic transmission in NK1R−/−mice could underlie their abnormal behaviour. Striatal dopaminergic transmission has long been linked with the modulation of locomotor activity. There is also evidence that disruption of mesocorticolimbic dopaminergic transmission gives rise to a lack of tolerance of delayed reward and contributes to impulsivity, a prominent feature of ADHD ([@bibr54-0269881108100255]; [@bibr42-0269881108100255]; [@bibr42-0269881108100255]; [@bibr14-0269881108100255]).

First, we compared dopamine efflux in the dorsal striatum. We studied this region because the activation of NK1R in either the substantia nigra ([@bibr49-0269881108100255]) or the striatum ([@bibr63-0269881108100255]; [@bibr37-0269881108100255]) increases striatal dopamine efflux. Further, although antagonism of NK1R within the striatum has no effect on substance P mRNA expression or spontaneous locomotor activity, it prevents a *d*-amphetamine-induced increase in both these measures ([@bibr28-0269881108100255]). NK1R antagonism in the striatum also prevents hyperactivity mediated by the activation of dopamine D1 receptors ([@bibr37-0269881108100255]). Against this background, we reasoned that basal dopamine efflux in the striatum would be unaffected by functional ablation of the NK1R gene, or NK1R antagonism, but that the dopamine response to *d*-amphetamine would be diminished.

As predicted, basal dopamine efflux did not differ in the two genotypes and was unaffected by NK1R antagonism. Evidently, spontaneous dopamine efflux in the dorsal striatum of these mice does not depend on tonic activation of NK1R. This is consistent with their low density on dopaminergic neurones in the substantia nigra, which project to the dorsal striatum.

Most, if not all, NK1R in the dorsal striatum are expressed by cholinergic interneurones ([@bibr26-0269881108100255]). Recent evidence suggests that these interneurones influence the activity of medium-spiny striatal output neurones ([@bibr65-0269881108100255]), and as a consequence, motor activity ([@bibr46-0269881108100255]). Striatal acetylcholine release is increased by the activation of dopamine D1-like receptors ([@bibr1-0269881108100255]) and this depends on functional NK1R ([@bibr61-0269881108100255]). Since cholinergic (M1) receptor knock-out mice are hyperactive ([@bibr25-0269881108100255]), one explanation for the hyperactivity of NK1R−/− mice could be that their lack of functional NK1R impairs acetylcholine release mediated by D1 receptor activation ([@bibr3-0269881108100255]). However, this is unlikely because basal dopamine efflux did not differ in the two genotypes and local activation of DRD1-like receptors induces hyperactivity, rather than reduces it ([@bibr37-0269881108100255]). An alternative explanation focuses on glutamatergic afferents from the cortex and thalamus, which converge on the cholinergic interneurones and medium-spiny output neurones. Glutamate-evoked acetylcholine release in the striatum is similarly facilitated by NK1R ([@bibr36-0269881108100255]). It follows that disruption of glutamate/NK1R/acetylcholine coupling could contribute to the hyperactivity of NK1R−/− mice. In either case, impaired NK1R function could account for hyperactivity in ADHD.

The administration of *d*-amphetamine increased extracellular dopamine in NK1R+/+ mice, but not in NK1R−/− mice or NK1R+/+ mice treated with RP 67580. It seems that the striatal dopamine response to *d*-amphetamine depends on functional NK1R. This is supported by evidence that antagonism of striatal NK1R prevents an increase in dopamine efflux following the administration of cocaine, another psychostimulant ([@bibr39-0269881108100255]). This difference in the dopamine response to *d*-amphetamine in the two genotypes could be explained by the absence of NK1R on noradrenergic neurones that project to the substantia nigra. This follows from reports that local infusion of substance P in the region of the locus coeruleus ([@bibr12-0269881108100255]) activates noradrenergic neurones and that the dopamine response to *d*-amphetamine in the dorsal striatum is attenuated in DβH−/− mice, which cannot synthesize noradrenaline ([@bibr55-0269881108100255]). The prevention of hyperactivity of NK1R−/− mice by *d*-amphetamine is harder to explain but the answer to this question could hold the key to its therapeutic effects in ADHD. We are currently testing our prediction, based on reports outlined above, that *d*-amphetamine increases acetylcholine efflux in the dorsal striatum of wild-type mice but not in mice lacking functional NK1R.

Next, we monitored dopamine efflux in the M2 subregion of the PFC. We studied this subregion for several reasons. First, in rats, the equivalent (Fr2) region has reciprocal connections with the locus coeruleus, forming part of a circuit that determines focussed attention/associative learning ([@bibr35-0269881108100255]; [@bibr34-0269881108100255]; [@bibr10-0269881108100255]). Secondly, all noradrenergic neurones in the locus coeruleus express NK1R ([@bibr13-0269881108100255]). Thirdly, ectopic uptake and release of dopamine by noradrenergic neurones in the PFC ([@bibr16-0269881108100255]) indicate functional coupling between these two groups of neurones.

Extracellular dopamine in the PFC of NK1R−/− mice was more than two-fold lower than that in the wild-type. This finding supports the view that ADHD involves a deficit in dopaminergic transmission in the PFC: 'hypofrontality' ([@bibr42-0269881108100255]; [@bibr47-0269881108100255]). The deficit in dopamine efflux was due to a lack of functional NK1R, rather than an extraneous compensatory response, because efflux in NK1R+/+ mice given RP 67580 progressively declined to that of NK1R−/−mice. In the rat ([@bibr56-0269881108100255]) and mouse (our unpublished data), dopaminergic neurones in the ventral tegmental area (which project to the PFC) express few, if any, NK1R and so these receptors are unlikely to have a direct effect on dopaminergic transmission in the PFC. Instead, the increased serotonin and/or noradrenaline transmission in NK1R−/− mice ([@bibr21-0269881108100255]; [@bibr27-0269881108100255]) could indirectly blunt transmitter release from dopaminergic neurones in the VTA (through activation of somatodendritic- or heteroceptors) ([@bibr29-0269881108100255]; [@bibr43-0269881108100255]). Whatever the explanation, the deficit in dopaminergic transmission in the prefrontal cortex could contribute to the hyperactivity in NK1R−/− mice and ADHD patients by disinhibiting glutamatergic (pyramidal cell) efferents that project from the PFC to the striatum ([@bibr38-0269881108100255]; [@bibr64-0269881108100255]). The increased serotonergic and noradrenergic transmission in NK1R−/−mice would also activate α~1~-adrenoceptors and 5-HT~2A~ receptors, which could further contribute to locomotor hyperactivity ([@bibr7-0269881108100255]).

*d*-Amphetamine did not affect dopamine efflux in the PFC of either genotype and so we infer that the difference in their behavioural response to *d*-amphetamine does not depend on its effects on extracellular dopamine in this region. Nevertheless, our findings indicate that functional ablation of the NK1R gene disrupts dopaminergic transmission in frontostriatal circuits, as well as that of noradrenergic and serotonergic neurones, all of which feature prominently in ADHD and are targeted by all the drugs that are currently used to treat this disorder.

Studies of the genetic susceptibility of humans similarly point to abnormal monoamine transmission in ADHD. So far, findings include genetic effects from the dopamine transporter (SLC6A3) gene, dopamine D4 (DRD4), and dopamine D5 receptor (DRD5) genes. It is interesting that DRD5 are expressed by cholinergic neurones in the dorsal striatum and the PFC ([@bibr8-0269881108100255]) where TACR1 (NK1R) is expressed. Weaker, albeit replicated, genetic evidence also supports the association between ADHD with the gene encoding synaptosomal-associated protein 25 kDa (SNAP-25) and the serotonin transporter (SLC6A4) gene ([@bibr5-0269881108100255]; [@bibr20-0269881108100255]; [@bibr62-0269881108100255]). However, the effect size of any of these variants is small and compatible with the known genetic heterogeneity of ADHD established by previous linkage studies.

It has already been suggested that it is the disruption of the interactions between monoamine transmitters that holds the key to this disorder ([@bibr42-0269881108100255]). Our evidence suggests that impaired NK1R function causes such an imbalance. Furthermore, the NK1R−/− mouse phenotype could incorporate functional abnormalities in gene products already associated with ADHD, either directly (e.g. by modifying the activity of noradrenergic projections to the prefrontal cortex and dorsal raphe nuclei) or indirectly (e.g. via cholinergic neurones in the striatum, which co-express dopamine D5 receptors and NK1R).

These findings prompted us to carry out genetic association studies to test for abnormalities in the TACR1 gene of patients with a diagnosis of ADHD. Our results revealed four SNPs that are positively associated with ADHD. This suggests that there are genetic variants, mutations or aetiological base-pair changes that alter the expression or function of the TACR1 receptor in ways that predispose to a subtype of ADHD. Because TACR1 SNPs are also associated with bipolar disorder, it is tempting to speculate that they genetically define a new clinical subtype of ADHD, which is more related to mood disorder than to conduct disorder. Three scenarios can be envisaged. The first is that different mutations in TACR1 could be responsible for ADHD and for bipolar disorder. The second is that the same mutations are responsible for bipolar disorder and ADHD, and therefore, there is a 'bipolar' subtype of ADHD, which is expressed in childhood as ADHD and later in life as bipolar disorder. Thirdly, it is possible that the same or another set of mutations in TACR1 predisposes to conduct disorder and explains the strongly established comorbidity between alcoholism and conduct disorder. The fact that TACR1 is associated with bipolar disorder both in our study and the study by [@bibr45-0269881108100255] seems to strengthen the first explanation and the likelihood that the association with alcoholism is mediated by TACR1 associated affective disorders, which are also strongly associated with alcoholism. These issues will best be resolved by further study of the TACR1 gene association in carefully clinically characterized subgroups of alcoholism with ADHD and subgroups of ADHD associated with dissocial personality or conduct disorder and by direct genomic resequencing of TACR1 in each of these TACR1 associated subgroups.

In conclusion, functional ablation of the NK1R gene causes neurochemical, pharmacodynamic, and behavioural changes in mice that resemble abnormalities in humans with ADHD and to a lesser extent resemble bipolar affective disorder. These findings provide compelling evidence that the SNPs in the TACR1 gene locus increase susceptibility to ADHD although replication in other samples is needed. New diagnostic, treatment and preventive strategies could emerge from further research of the molecular pathology of NK1R/TACR1 gene expression and the function of this receptor.
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